NASDAQ$BLFS

BioLife Solutions Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

BioLife Solutions reported financial results for the third quarter of 2023, which were in line with expectations, with biostorage services exhibiting strong ex-COVID growth, while the company is working on divesting its freezer operations.

BioLife Solutions announced its Q3 2023 financial results, with total revenue of $33.3 million. The company is focusing on adapting and innovating as a leading provider of cell processing tools and biostorage services, with a strategic emphasis on the high-margin, recurring biopreservation media revenue.

  • Total revenue for Q3 2023 was $33.3 million, an 18% decrease from Q3 2022.
  • Cell Processing platform revenue was $13.3 million, a 26% decrease year-over-year
  • Biostorage and Services platform revenue was $6.6 million, a 10% decrease year-over-year, but ex-COVID related revenue grew 50%.
  • The company is working on the divestiture of the freezer operations, expected to conclude in early 2024.

Headline financials

Total Revenue

$33.3M

Previous: $40.7M-18.2%
EPS (adj)

-$0.33

Previous: -$0.15-120.0%
GAAP gross margin

33.0%

Previous: 31.0%+6.5%
Non-GAAP adjusted gross margin

30.0%

Previous: 34.0%-11.8%
GAAP operating loss

-$28.8M

Previous: -$11.4M-152.6%
Adjusted EBITDA

-$3.1M

Previous: $1.4M-321.4%
Capital Expenditures

-$5.4M

Previous: -$5.94M+9.0%
Free Cash Flow

-$34.5M

Previous: -$15.9M-117.3%
Net Income

-$29.1M

Previous: -$9.96M-192.6%
Operating Income

-$28.8M

Previous: -$11.4M-152.4%
Gross Profit

$10.9M

Previous: $12.6M-13.5%
Cash & Equivalents

$19.2M

Previous: $27M-28.9%
Total Assets

$411M

Previous: $488M-15.7%
R&D Expense

$5.4M

No prior period
Stock-Based Comp

$9.12M

Previous: $6.3M+44.7%

Revenue & EPS history

BioLife · Revenue · Quarterly

$33.3M

Q3 2023-18.2%vs Q3 2022
Beat estimate in 11 of 14 quarters(79%)
ActualEstimate

Revenue by segment

BioLife · $19.9M total across 2 segments · Q3 2023

  • Cell Processing platform
    $13.3M-26.5%
  • evo and Thaw platform
    $6.6M

Forward guidance

BioLife Solutions anticipates full year 2023 revenue to be at the low end of the previously announced guidance range of $144 million to $158 million. Revenue expectations include approximately $65 million from the Cell Processing platform, $26 million from the Biostorage and Services platform, and $53 million from the Freezers and Thaw Systems platform.

Tailwinds

  • Cell Processing platform: Approximately $65 million, assumes flat to modest sequential growth for the cell processing platform in the fourth quarter.
  • Biostorage and Services platform: Approximately $26 million, year-over-year growth of 61% excluding COVID-related revenue.
  • The Company expects to bring the divestiture process to a conclusion in early 2024.
  • The Company’s streamlined financial profile will benefit immediately from the operating leverage provided by the high margin, recurring biopreservation media revenue.

Headwinds

  • Total 2023 and Freezers and Thaw Systems platform revenue may be impacted by the timing of the freezer product line divestitures.
  • Full year 2023 revenue is expected to reflect a year-over-year decrease of 11%, and excluding COVID related revenue in 2022, a year-over year decrease of 3%.
  • Freezers and Thaw Systems platform: Approximately $53 million a decrease of 21% compared to 2022, and excluding COVID-related revenue, a year-over-year decrease of 18%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+4.3%

Avg return

30 days after

44%

22 / 50 earnings

Positive

+21.4%

Q3 2022

Best reaction

-34.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.3%-2.4%+22.4%
Q4 2025+8.0%-8.1%-17.3%
Q3 2025-4.2%-4.1%-5.8%
Q2 2025+10.0%+24.4%+28.2%
Q1 2025+4.0%-1.4%+6.0%
Q4 2024+2.1%+7.6%-0.9%
Q3 2024-9.4%-21.0%+0.5%
Q2 2024+14.5%+20.3%+7.9%
Q1 2024+8.9%+25.0%+13.2%
Q4 2023+5.1%-0.5%+8.5%
Q3 2023-5.7%+3.1%+14.2%
Q2 2023-29.7%-34.9%-30.3%
Q1 2023-2.9%+3.5%+20.6%
Q4 2022+0.2%+2.7%-7.4%
Q3 2022+21.4%+14.1%-4.6%
Q2 2022+13.7%+15.7%+25.6%
Q1 2022-3.8%+1.6%+18.3%
Q4 2021-0.3%+0.9%-3.7%
Q3 2021-6.0%+5.2%-30.3%
Q2 2021-1.8%-3.9%+12.0%
Q1 2021-2.1%+4.8%+25.1%
Q4 2020+8.3%-7.8%-14.7%
Q3 2020+5.8%+0.8%+21.6%
Q2 2020+0.3%-5.4%+5.6%
Q1 2020+3.0%+10.5%+1.5%
Q4 2019-34.5%-36.7%-27.8%
Q3 2019-12.8%-8.8%-7.4%
Q2 2019-6.2%+1.1%+7.7%
Q1 2019-2.4%+4.5%+8.8%
Q4 2018+10.7%+19.4%+5.5%
Q3 2018+15.0%-8.0%-7.8%
Q2 2018-4.8%-1.0%+2.3%
Q1 2018-3.7%+7.6%+23.5%
Q4 2017-4.4%-10.2%+22.4%
Q3 2017+18.0%+21.6%+8.2%
Q2 2017+3.8%+8.2%+30.6%
Q1 2017+3.7%-1.4%+7.8%
Q4 2016-5.0%-9.5%-7.7%
Q3 2016+0.7%+2.7%+5.4%
Q2 2016-2.4%-7.7%-15.9%
Q3 2012+10.0%
Q1 2012+0.0%
Q4 2011+0.0%
Q3 2011+0.0%
Q2 2011-14.3%
Q1 2011+0.0%
Q4 2010-11.1%
Q3 2010+0.0%
Q2 2010+0.0%
Q1 2010+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro